Literature DB >> 31727408

Osteoarthritis: a new short-term treatment option?

Graeme Jones1, Tania Winzenberg2.   

Abstract

Entities:  

Year:  2019        PMID： 31727408     DOI： 10.1016/S0140-6736(19)32729-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment.

Authors:  Yujie Liang; Xiao Xu; Limei Xu; Zoya Iqbal; Kan Ouyang; Huawei Zhang; Chunyi Wen; Li Duan; Jiang Xia
Journal:  Theranostics       Date:  2022-06-21       Impact factor: 11.600

2.  Cartilage-targeting peptide-modified dual-drug delivery nanoplatform with NIR laser response for osteoarthritis therapy.

Authors:  Song Xue; Xiaojun Zhou; Weilin Sang; Cong Wang; Haiming Lu; Yiming Xu; Yiming Zhong; Libo Zhu; Chuanglong He; Jinzhong Ma
Journal:  Bioact Mater       Date:  2021-01-26

3.  Osteopontin inhibits osteoarthritis progression via the OPN/CD44/PI3K signal axis.

Authors:  Qing Liu; Hao Zeng; Yuhao Yuan; Zhiwei Wang; Ziyi Wu; Wei Luo
Journal:  Genes Dis       Date:  2020-06-27

4.  Pseudolaric acid B ameliorates synovial inflammation and vessel formation by stabilizing PPARγ to inhibit NF-κB signalling pathway.

Authors:  Jiansen Lu; Hong Guan; Dan Wu; Zhiqiang Hu; Hongbo Zhang; Huaji Jiang; Jingyao Yu; Ke Zeng; Hongyu Li; Haiyan Zhang; Chenglong Pan; Daozhang Cai; Xiao Yu
Journal:  J Cell Mol Med       Date:  2021-06-11       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.